A Phase 4 interventional study of mosapride for the first month and placebo for the 2nd month and placebo for the first and mosapride for the second month in Gastroesophageal Reflux Disease, sponsored by Lotung Poh-Ai Hospital. Completed at 1 site in Taiwan. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2009-05-13.
Sponsored by Lotung Poh-Ai Hospital · Phase 4, Interventional, and Treatment
Gastroesophageal reflux disease (GERD) is a very common disease in the Western World. In Taiwan, this disease is increasing gradually because the investigators' eating style is closing to Western world.
Proton pump is the main drug for patients with GERD in the past two decades. Prokinetic agent is an important adjuvant to the therapy of GERD. This study aims to evaluate the role of prokinetic agent in the management of GERD.
This is a randomized, double-blind, cross-over study. FSSG is obtained at the beginning, one month and two months of the study.
This study plans to enroll 100 patients with symptoms of GERD (acid regurgitation, belching, dysphagia). After receiving endoscopic examination, a frequent scale for the symptoms of gastroesophageal reflux disease (FSSG) is obtained from these patients. Fifty patients receive lansoprazole 30 mg once plus mosapride 5 mg tid daily in the first month; and lansoprazole 30 mg once plus placebo tid daily in the second month. Another fifty patients receive lansoprazole 30 mg once plus placebo tid daily in the first month; and lansoprazole 30 mg once plus mosapride 5 mg tid daily in the second month.
1,067 studies on the registry are indexed under Gastroesophageal Reflux; 188 are open to participants now.
This study's enrollment of 114 is above the median of 72 across 712 interventional studies indexed under Gastroesophageal Reflux.
Browse Gastroesophageal Reflux studies →Lotung Poh-Ai Hospital is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
lansoprazole plus mosapride for the first month, and followed by lansoprazole plus placebo for the second month
Drug: mosapride for the first month and placebo for the 2nd month
lansoprazole plus placebo for the first month, and lansoprazole plus mosapride for the second month
Drug: placebo for the first and mosapride for the second month
lansoprazole 30 mg once per day for 2 months mosapride 5 mg thrice per day, for the first month placebo thrice per day, for the second month
lansoprazole 30 mg once per day for 2 months placebo thrice per day, for the first month mosapride 5 mg thrice per day, for the second month
Symptom improvement evaluated by frequent scale for the symptoms of gastroesophageal reflux disease (FSSG)
Time frame: before enrollment, one month after treatment, two months after treatment
This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lotung Poh-Ai Hospital